$LONA News
Last published 2mo ago
- 2mo agoLONALeonaBio to Participate in Cantor Global Healthcare Conference 2026GlobeNewswireBOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical
- 2mo agoLONAMRUSLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireOn Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL,
- 3mo agoLONALeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast CancerGlobeNewswireBOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 5mo agoLONALeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitGlobeNewswireBOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 5mo agoLONALeonaBio to Participate in Upcoming Medical and Industry Meetings in JuneGlobeNewswireBOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 6mo agoLONAMRUSLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete
- 6mo agoLONAMRUSLeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.GlobeNewswireBOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 6mo agoLONALeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast CancerGlobeNewswireManagement to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data
- 6mo agoLONAIndependent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's DataGlobeNewswireBOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 7mo agoLONALeonaBio Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireAcquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with
- 9mo agoLONALeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business OfficerGlobeNewswireBOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 10mo agoLONAATHIRA UPDATE - LEONABIO INCEarnings Call TranscriptsHello, ladies and gentlemen. Thank you for standing by and welcome to the Athera Pharma Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question and